Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.

PHARMACIE NICE EUROPE : revenue, balance sheet and financial ratios

PHARMACIE NICE EUROPE is a French company founded 15 years ago, specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé. Based in NICE (06000), this company of category PME shows in 2016 a revenue of 1.6 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-02

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - PHARMACIE NICE EUROPE (SIREN 525036976)
Indicator 2021 2020 2019 2018 2017 2016
Revenue N/C N/C N/C N/C N/C 1 558 284 €
Net income 241 697 € 81 407 € 55 412 € 32 540 € 138 361 € 96 063 €
EBITDA N/C N/C N/C N/C N/C 121 183 €
Net margin N/C N/C N/C N/C N/C 6.2%

Revenue and income statement

In 2021, PHARMACIE NICE EUROPE generates positive net income of 242 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2016-2021: 96 k€ -> 242 k€.

Net income (2021) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

241 697 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 166%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 33%. The balance between equity and debt is satisfactory.

Debt ratio (2021) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

165.771%

Financial autonomy (2021) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

32.541%

Asset age ratio (2021) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

13.8%

Solvency indicators evolution
PHARMACIE NICE EUROPE

Sector positioning

Debt ratio
165.77 2021
2019
2020
2021
Q1: 29.03
Med: 85.54
Q3: 208.44
Average -9 pts over 3 years

In 2021, the debt ratio of PHARMACIE NICE EUROPE (165.77) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.

Financial autonomy
32.54% 2021
2019
2020
2021
Q1: 25.88%
Med: 44.4%
Q3: 64.18%
Average +9 pts over 3 years

In 2021, the financial autonomy of PHARMACIE NICE EUROPE (32.5%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 186.72. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2021) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

186.719

Liquidity indicators evolution
PHARMACIE NICE EUROPE

Sector positioning

Liquidity ratio
186.72 2021
2019
2020
2021
Q1: 139.19
Med: 190.69
Q3: 259.61
Average +7 pts over 3 years

In 2021, the liquidity ratio of PHARMACIE NICE EUROPE (186.72) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 176 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 588 days. Excellent situation: suppliers finance 412 days of the operating cycle (retail model).

Operating WCR (2021) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2021) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

176 j

Supplier credit (2021) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

588 j

Inventory turnover (2021) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
PHARMACIE NICE EUROPE

Positioning of PHARMACIE NICE EUROPE in its sector

Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé

Valuation estimate

Based on 220 transactions of similar company sales in 2021, the value of PHARMACIE NICE EUROPE is estimated at 2 772 365 € (range 1 782 644€ - 4 282 432€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2021
220 transactions
1782k€ 2772k€ 4282k€
2 772 365 € Range: 1 782 644€ - 4 282 432€
NAF 5 année 2021

Valuation method used

Net Income Multiple
241 697 € × 11.5x = 2 772 365 €
Range: 1 782 644€ - 4 282 433€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 220 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)

Compare PHARMACIE NICE EUROPE with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de détail de produits pharmaceutiques en magasin spécialisé

Frequently asked questions about PHARMACIE NICE EUROPE

What is the revenue of PHARMACIE NICE EUROPE ?

The revenue of PHARMACIE NICE EUROPE in 2016 is 1.6 M€.

Is PHARMACIE NICE EUROPE profitable?

Yes, PHARMACIE NICE EUROPE generated a net profit of 242 k€ in 2021.

Where is the headquarters of PHARMACIE NICE EUROPE ?

The headquarters of PHARMACIE NICE EUROPE is located in NICE (06000), in the department Alpes-Maritimes.

Where to find the tax return of PHARMACIE NICE EUROPE ?

The tax return of PHARMACIE NICE EUROPE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does PHARMACIE NICE EUROPE operate?

PHARMACIE NICE EUROPE operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.